Does antiretroviral therapy improve HIV-associated cognitive impairment? A quantitative review of the literature

Journal of the International Neuropsychological Society

Volumn 17, Issue 6, 2011, Pages 956-969

  Al Khindi, Timour ^a   Zakzanis, Konstantine K ^a   Van Gorp, Wilfred G ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

Acquired immune deficiency syndrome; Antiretroviral therapy; Cognitive outcome; Human immunodeficiency virus; Meta analysis; Neuropsychological assessment

Indexed keywords

EID: 80455156058     PISSN: 13556177     EISSN: 14697661     Source Type: Journal    
DOI: 10.1017/S1355617711000968     Document Type: Review

References (65)

1. References preceded by an asterisk were included in the metaanalysis.
2. Adamson, C.S., & Freed, E.O. (2008). Recent progress in antiretrovirals-Lessons from resistance. Drug Discovery Today, 13, 424-432.
3. Anthony, I.C., Ramage, S.N., Carnie, F.W., Simmonds, P., & Bell, J.E. (2005). Influence of HAART on HIV-related CNS disease and neuroinflammation. Journal of Neuropathology and Experimental Neurology, 64, 529-536.
4. Aylward, E.H., Henderer, J.D., McArthur, J.C., Brettschneider, P.D., Harris, G.J., Barta, P.E., & Pearlson, G.D. (1993). Reduced basal ganglia volume in HIV-1-associated dementia: Results from quantitative neuroimaging. Neurology, 43, 2099-2104.
5. Baldeweg, T., Catalan, J., Lovett, E., Gruzelier, J., Riccio, M., & Hawkins, D. (1995). Long-term zidovudine reduces neurocognitive deficits in HIV-1 infection. AIDS, 9, 589-596.
6. Borenstein, M., Hedges, L.V., Higgins, J.P.T., & Rothstein, H.R. (2009). Introduction to meta-analysis. West Sussex, UK: John Wiley & Sons, Ltd.
7. Brouwers, P., Hendricks, M., Lietzau, J.A., Pluda, J.M., Mitsuya, H., Broder, S., & Yarchoan, R. (1997). Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease: A comparison of simultaneous and alternating regimens. AIDS, 11, 59-66.
8. Carr, A. (2003). Toxicity of antiretroviral therapy and implications for drug development. Nature Reviews Drug Discovery, 2, 624-634.
9. Carvalhal, A.S., Rourke, S.B., Belmonte-Abreu, P., Correa, J., & Goldani, L.Z. (2006). Evaluation of neuropsychological performance of HIV-infected patients with minor motor cognitive dysfunction treated with highly active antiretroviral therapy. Infection, 24, 357-360.
10. Chang, L., Ernst, T., Witt, M.D., Ames, N., Walot, I., Jovicich, J.,Miller, E.N. (2003). Persistent brain abnormalities in antiretroviral- naïve HIV patients 3 months after HAART. Antiviral Therapy, 8, 17-26.
11. Chen, Y., An, H., Zhu, H., Stone, T., Smith, J.K., Hall, C.,Lin, W. (2009). White matter abnormalities revealed by diffusion tensor imaging in non-demented and demented HIV1 patients. Neuroimage, 47, 1154-1162.
12. Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Erlbaum Associates.
13. Cohen, R.A., Boland, R., Paul, R., Tashima, K.T., Schoenbaum, E.E., Celentano, D.D.,Carpenter, C.C. (2001). Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women. AIDS, 15, 341-345.
14. Cooper, H., & Hedges, L.V. (1994). The handbook of research synthesis. New York: Russell Sage Foundation.
15. Cysique, L.A., & Brew, B.J. (2009). Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: A review. Neuropsychology Review, 19, 169-185.
16. Duval, S., & Tweedie, R. (2000a). A nonparametric 'trim and fill' method of accounting for publication bias in meta-analysis. Journal of the American Statistical Association, 95, 89-98.
17. Duval, S., & Tweedie, R. (2000b). Trim and fill: A simple funnelplot-based method of testing and adjusting for publication bias in meta analysis. Biometrics, 56, 455-463.
18. Ferrando, S., van Gorp, W., McElhiney, M., Goggin, K., Sewell, M., & Rabkin, J. (1998). Highly active antiretroviral treatment in HIV infection: Benefits for neuropsychological function. AIDS, 12, F65-F70.
19. Fischl, M.A., Richman, D.D., Grieco, M.H., Gottlieb, M.S., Volberding, P.A., Laskin, O.L.,King, D. (1987). The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine, 317, 185-191.
20. Goldstein, G. (1984). Comprehensive neuropsychological assessment batteries. In G. Goldstein & M. Herson (Eds.), Handbook of psychological assessment (pp. 181-210). New York, NY: Pergamon Press.
21. Hammer, S.M., Squires, K.E., Hughes, M.D., Grimes, J.M., Demeter, L.M., Currier, J.S.,Fischl, M.A. (1997). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS clinical trials group 320 study team. New England Journal of Medicine, 337, 725-733.
22. Hayman-Abello, S.E. (2006). The effects of highly active antiretroviral therapy (HAART) on neuropsychological status in HIV-infection: A prospective study. Dissertation Abstracts International: Section B: The Sciences and Engineering, 67, 4106.
23. Heaton, R.K., Chelune, G.J., Talley, J., Kay, G.G., & Curtiss, G. (1993). Wisconsin Card Sorting Test manual-revised and expanded. Odessa, FL: Psychological Assessment Resources.
24. Heaton, R.K., Clifford, D.B., Franklin, D.R., Jr., Woods, S.P., Ake, C., Vaida, F.,Grant, I. (2010). HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology, 75, 2087-2096.
25. Heaton, R.K., Franklin, D.R., Ellis, R.J., McCutchan, J.A., Letendre, S.L., Leblanc, S.,Grant, I. (2011). HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: Differences in rates, nature, and predictors. Journal of Neurovirology, 17, 3-16.
26. Hedges, L.V., & Olkin, I. (1985). Statistical methods for metaanalysis. Orlando, FL: Academic Press.
27. Hunter, J.E., & Schmidt, F.L. (1990). Methods of meta-analysis. Newbury Park, CA: Sage Publications.
28. Joska, J.A., Gouse, H., Paul, R.H., Stein, D.J., & Flisher, A.J. (2010). Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. Journal of Neurovirology, 16, 101-114.
29. Lezak, M.D., Howieson, D.B., & Loring, D.W. (2004). Neuropsychological assessment (4th ed.). New York, NY: Oxford University Press.
30. Lindsey, J.C., Malee, K.M., Brouwers, P., &Hughes, M.D. (2007). Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy. Pediatrics, 119, e681-e693.
31. Liner, K.J., Jr., Hall, C.D., & Robertson, K.R. (2008). Effects of antiretroviral therapy on cognitive impairment. Current HIV/AIDS Reports, 5, 64-71.
32. Liner, K.J., Jr., Ro, M.J., & Robertson, K.R. (2010). HIV, antiretroviral therapies, and the brain. Current HIV/AIDS Reports, 7, 85-91.
33. Lipsey, M.W., & Wilson, D.B. (1993). The efficacy of psychological, educational, and behavioral treatment. American Psychologist, 12, 1181-1209.
34. Llorente, A.M., van Gorp, W.G., Stern, M.J., George, L., Satz, P., Marcotte, T.D., & Hinkin, C.H. (2001). Long-term effects of high-dose zidovudine on neuropsychological performance in mildly symptomatic HIV-positive patients: Results of a randomized, double-blind, placebo-controlled investigation. Journal of the International Neuropsychological Society, 7, 27-32.
35. Martin, E.M., Pitrak, D.L., Novak, R.M., Pursell, K.J., & Mullane, K.M. (1999). Reaction times are faster in HIV-seropositive patients on antiretroviral therapy: A preliminary report. Journal of Clinical and Experimental Neuropsychology, 21, 730-735.
36. Marzolini, C., Telenti, A., Decosterd, L.A., Greub, G., Biollaz, J., & Buclin, T. (2001). Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS, 15, 71-75.
37. McArthur, J.C., Steiner, J., Sacktor, N., & Nath, A. (2010). Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap. Annals of Neurology, 67, 699-714.
38. Millikin, C.P., Trépanier, L.L., & Rourke, S.B. (2005). Verbal fluency component analysis in adults with HIV/AIDS. Journal of Clinical and Experimental Neuropsychology, 26, 933-942.
39. Mocroft, A., Phillips, A.N., Gatell, J., Ledergerber, B., Fisher, M., Clumeck, N.,Lundgren, J.D. (2007). Normalization of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: An observational cohort study. Lancet, 370, 407-413.
40. Orenstein, J.M., Fox, C.,&Wahl, S.M. (1997). Macrophages as a source of HIV during opportunistic infections. Science, 276, 1857-1861.
41. Orwin, R.G. (1983). A fail-safe N for effect size in meta-analysis. Journal of Educational Statistics, 8, 157-159.
42. Reger, M., Welsh, R., Razani, J., Martin, D.J., & Boone, K.B. (2002). A meta-analysis of the neuropsychological sequelae of HIV infection. Journal of the International Neuropsychological Society, 8, 410-424.
43. Richardson, J.L., Martin, E.M., Jiminez, N., Danley, K., Cohen, M., Carson, V.L.,Levine, A.M. (2002). Neuropsychological functioning in a cohort of HIV infected women: Importance of antiretroviral therapy. Journal of the International Neuropsychological Society, 8, 781-793.
44. Robertson, K.R., Robertson, W.T., Ford, S., Watson, D., Fiscus, S., Harp, A.G., & Hall, C.D. (2004). Highly active antiretroviral therapy improves neurocognitive functioning. Journal of Acquired Immune Deficiency Syndromes, 36, 562-566.
45. Robertson, K.R., Smurzynski, M., Parsons, T.D., Wu, K., Bosch, R.J., Wu, J.,Ellis, R.J. (2007). The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS, 21, 1915-1921.
46. Rosenthal, R. (1991). Meta-analytic procedures for social research. Beverly Hills, CA: Sage Publications.
47. Rosenthal, R. (1995). Writing meta-analytic reviews. Psychological Bulletin, 118, 183-192.
48. Sacktor, N. (2002). The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. Journal of Neurovirology, 8, 115-121.
49. Sacktor, N.C., Lyles, R.H., Skolasky, R.L., Anderson, D.E., McArthur, J.C., McFarlane, G.,Miller, E.N. (1999). Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Multicenter AIDS cohort study (MACS). Neurology, 52, 1640-1647.
50. Sacktor, N., McDermott, M.P., Marder, K., Schitto, G., Selnes, O.A., McArthur, J.C.,Epstein, L. (2002). HIV-associated cognitive impairment before and after the advent of combination therapy. Journal of Neurovirology, 8, 136-142.
51. Sacktor, N., Nakasujja, N., Skolasky, R., Robertson, K., Wong, M., Musisi, S.,Clifford, D.B. (2009). Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology, 72, 165-170.
52. Sacktor, N., Nakasujja, N., Skolasky, R., Robertson, K., Wong, M., Musisi, S.,Katabira, E. (2006). Antiretroviral therapy improves cognitive impairment in HIV1 individuals in sub-Saharan Africa. Neurology, 67, 311-314.
53. Squire, L.R., Stark, C.E., & Clark, R.E. (2004). The medial temporal lobe. Annual Review of Neuroscience, 27, 279-306.
54. Strauss, E., Sherman, E.M.S., & Spreen, O. (2006). A compendium of neuropsychological tests: Administration, norms and commentary (3rd ed.). New York, NY: Oxford University Press.
55. Suarez, S., Baril, L., Stankoff, B., Khellaf,M., Dubois, B., Lubetzki, C.,Hauw, J. (2001). Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy. AIDS, 15, 195-200.
56. Sun, B., Abadjian, L., Rempel, H., Calosing, C., Rothlind, J., & Pulliam, L. (2010). Peripheral biomarkers do not correlate with cognitive impairment in highly active antiretroviral therapytreated subjects with human immunodeficiency virus type 1 infection. Journal of Neurovirology, 16, 115-124.
57. Thompson, P.M., Dutton, R.A., Hayashi, K.M., Toga, A.W., Lopez, O.L., Aizenstein, H.J., & Becker, J.T. (2005). Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD41 T lymphocyte decline. Proceedings of the National Academy of Sciences of the United States of America, 102, 15647-15652.
58. Tozzi, V., Balestra, P., Bellagamba, R., Corpolongo, A., Salvatori, M.F., Visco-Comandini, U.,Narciso, P. (2007). Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: Prevalence and risk factors. Journal of Acquired Immune Deficiency Syndromes, 45, 174-182.
59. Tozzi, V., Balestra, P., Galgani, S., Narciso, P., Ferri, F., Sebastiani, G.,Benedetto, A. (1999). Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS, 13, 1889-1897.
60. Tozzi, V., Balestra, P., Galgani, S., Pasquale, N., Sampaolesi, A., Antinori, A.,Ippolito, G. (2001). Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years. Journal of Acquired Immune Deficiency Syndromes, 28, 19-27.
61. Tozzi, V., Balestra, P., Salvatori, M.F., Vlassi, C., Liuzzi, G., Giancola, M.L.,Antinori, A. (2009). Changes in cognition during antiretroviral therapy: Comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. Journal of Acquired Immune Deficiency Syndromes, 52, 56-63.
62. Tozzi, V., Narciso, P., Galgani, S., Sette, P., Balestra, P., Gerace, C.,Visco, G. (1993). Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex. AIDS, 7, 683-692.
63. Winston, A., Duncombe, C., Li, P.C., Gill, J.M., Kerr, S.J., Puls, R.,Cooper, D.A. (2010). Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized controlled study. Clinical Infectious Diseases, 50, 920-929.
64. Zakzanis, K.K. (1998). Brain is related to behavior (p,.05). Journal of Clinical and Experimental Neuropsychology, 20, 419-427.
65. Zakzanis, K.K. (2001). Statistics to tell the truth, the whole truth, and nothing but the truth: Formulae, illustrative numerical examples, and heuristic interpretation of effect size analyses for neuropsychological researchers. Archives of Clinical Neuropsychology, 16, 653-667.